As of November 9, 2026, 10 holders' latest Schedule 13D or 13G filings report owning 5% or more of Minerva Neurosciences Inc. The largest reported stake is Federated Hermes, Inc.'s, at 17.17%. 16 filings are on record since October 28, 2025 (Schedule 13G/A, July 8, 2026).
Sell to companies like Minerva Neurosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: BlackRock, Inc. · Percent: 5.1% · SCHEDULE 13G
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 4,654,212 · Shared voting: 0 · Sole dispositive: 4,654,212 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 4,730,000 · Sole dispositive: 0 · Shared dispositive: 4,730,000 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Federated Hermes, Inc. · Sole voting: 8,690,926 · Shared voting: 0 · Sole dispositive: 8,690,926 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-08
- · Holder: Balyasny Asset Management L.P. · Percent: 9.99% · SCHEDULE 13G/A
Minerva Neurosciences Inc has 16 Schedule 13D or 13G filings on record since 2025-10-28. 10 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Federated Hermes, Inc. | 17.17% | 8,690,926 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
| 9.99% | 4,539,854 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 | |
| Vivo Opportunity Fund Holdings, L.P. | 9.99% | 8,591,572 | SCHEDULE 13G, 2025-12-31 | 2025-12-23 |
| Balyasny Asset Management L.P. | 9.99% | 4,654,212 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Coastlands Capital LP | 9.99% | 4,563,031 | SCHEDULE 13G, 2026-02-20 | 2026-02-13 |
| Logos Global Management LP | 9.9% | 4,435,444 | SCHEDULE 13G, 2026-02-17 | 2025-12-23 |
| Janus Henderson Group Plc | 9.9% | 4,307,759 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Farallon Capital Management, L.L.C. | 9.7% | 4,730,000 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Adage Capital Management, L.P. | 6.35% | 2,838,000 | SCHEDULE 13G, 2026-02-12 | 2025-12-31 |
| BlackRock, Inc. | 5.1% | 2,450,284 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Boehringer AG | 3.4% | 1,500,225 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-23 |
Holding shares or following this stake? See who's behind Minerva Neurosciences Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Minerva Neurosciences Inc and the records around it.
Minerva Neurosciences Inc elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Watch Minerva Neurosciences Inc
Get an email when Minerva Neurosciences Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Minerva Neurosciences Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Minerva Neurosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Minerva Neurosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 8,690,926 | 0 | 8,690,926 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Voting Shares Irrevocable Trust | 8,690,926 | 0 | 8,690,926 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Thomas R. Donahue | 0 | 8,690,926 | 0 | 8,690,926 | SCHEDULE 13G/A, 2026-07-08 |
| Ann C. Donahue | 0 | 8,690,926 | 0 | 8,690,926 | SCHEDULE 13G/A, 2026-07-08 |
| J. Christopher Donahue | 0 | 8,690,926 | 0 | 8,690,926 | SCHEDULE 13G/A, 2026-07-08 |
| Balyasny Asset Management L.P. | 4,654,212 | 0 | 4,654,212 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Bam Gp LLC | 4,654,212 | 0 | 4,654,212 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 4,654,212 | 0 | 4,654,212 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dames GP LLC | 4,654,212 | 0 | 4,654,212 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dmitry Balyasny | 4,654,212 | 0 | 4,654,212 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Management, L.L.C. | 0 | 4,730,000 | 0 | 4,730,000 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital F5 Master I, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Partners, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Institutional (GP) V, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon F5 (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Dapice Joshua J. | 0 | 4,730,000 | 0 | 4,730,000 | SCHEDULE 13G/A, 2026-08-13 |
| Dreyfuss, Philip D. | 0 | 4,730,000 | 0 | 4,730,000 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Minerva Neurosciences Inc by CUSIP 603380205 and gives its principal executive office as 1500 District Avenue, Burlington, MA 01803 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares, based on 46,588,709 Shares outstanding as of April 30, 2026, as reported in the Issuer's form 10-Q with the Securities and Exchange Commission on May 5, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Boehringer AG
There are no material updates to the Original Filing.Item 4 of the SCHEDULE 13D/A filed 2025-12-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-28 | Federated Hermes, Inc. | 19.32% | SCHEDULE 13D |
| 2025-12-29 | Dapice Joshua J. | 9.99% | SCHEDULE 13G |
| 2025-12-29 | Federated Hermes, Inc. | 19.86% | SCHEDULE 13G |
| 2025-12-30 | Boehringer AG | 3.4% | SCHEDULE 13D/A |
| 2025-12-31 | Vivo Opportunity Fund Holdings, L.P. | 9.99% | SCHEDULE 13G |
| 2026-02-05 | Dapice Joshua J. | 9.99% | SCHEDULE 13G/A |
| 2026-02-12 | Adage Capital Management, L.P. | 6.35% | SCHEDULE 13G |
| 2026-02-17 | Logos Global Management LP | 9.9% | SCHEDULE 13G |
| 2026-02-17 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G |
| 2026-02-20 | Coastlands Capital LP | 9.99% | SCHEDULE 13G |
| 2026-05-15 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 9.9% | SCHEDULE 13G |
| 2026-07-08 | Federated Hermes, Inc. | 17.17% | SCHEDULE 13G/A |
| 2026-08-13 | Farallon Capital Management, L.L.C. | 9.7% | SCHEDULE 13G/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
Questions about who owns Minerva Neurosciences Inc
Who owns Minerva Neurosciences Inc?
On this page, 10 holders' latest ownership filings report 5% or more of Minerva Neurosciences Inc: Federated Hermes, Inc. (17.17%, Schedule 13G/A, filed 2026-07-08), Dapice Joshua J. (9.99%, Schedule 13G/A, filed 2026-02-05), Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G, filed 2025-12-31), Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14) and Coastlands Capital LP (9.99%, Schedule 13G, filed 2026-02-20); 5 more are listed above.
Who are the largest shareholders of Minerva Neurosciences Inc?
By the share each holder's latest filing reports, the largest holders of Minerva Neurosciences Inc on this page are Federated Hermes, Inc. (17.17%), Dapice Joshua J. (9.99%) and Vivo Opportunity Fund Holdings, L.P. (9.99%).
When did Federated Hermes, Inc. buy into Minerva Neurosciences Inc?
The filings give report dates, not purchase dates. The earliest filing from Federated Hermes, Inc. on this page is the Schedule 13D, filed 2025-10-28, reporting 19.32%; its latest, Schedule 13G/A filed 2026-07-08, reports 17.17%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Minerva Neurosciences Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 12, 2026 | Leadership change: Anthony Aliquo appointed, Chief Accounting Officer, and 1 more | — | Leadership changes | Source |
| April 2, 2026 | Leadership change: Geoffrey Race departs, President | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Minerva Neurosciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.